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Background: The genetic characterization of obese in-
dividuals could clarify the molecular mechanisms un-
derlying body weight regulation and lead to targeted
therapy. Here we report variants of the proopiomelano-
cortin (POMC) and melanocortin receptor 4 (MC4R)
genes detected in severely obese adults living in south-
ern Italy.
Methods: A total of 196 unrelated nondiabetic severely
obese individuals [111 females and 85 males; mean (SD)
age, 32.2 (11.5) years; mean body mass index, 48.8 (8.1)
kg/m2] and 100 normal-weight healthy volunteers (34
males and 66 females) entered the study. POMC and
MC4R were genotyped by sequencing analysis. Leptin,
insulin, glucose, and the lipid profile were measured in
fasting serum samples. We used the protein truncation
test to verify the stop-codon mutation. Anthropometric
measurements, sitting blood pressure, and heart rate
were also recorded.
Results: Of the obese participants, 1.5% had mutations
in POMC exon 3 (new mutations, P231L and E244X;
known, R236G) and 2.5% had MC4R mutations (new
mutations, W174C, Q43X, S19fsX51, and I317V; known,
A175T). These mutations were not present in the con-
trols. Gene polymorphisms were identified in similar
percentages of severely obese and nonobese individu-
als, i.e., respectively, 52.5% and 51% (POMC) and 1%
and 2% (MC4R).
Conclusions: We detected 2 new POMC mutations and
4 new MC4R mutations in a large number of severely
obese adults living in southern Italy. These mutations,
not present in normal-weight individuals, are further
evidence that defects in the melanocortin pathway are
related to severe obesity.
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Obesity is caused by a dysregulation in energy homeosta-
sis that promotes an increase in body fat stores (1 ). The
neuroendocrine system regulates energy balance by con-
trolling appetite, as well as food intake and utilization
(2, 3). Leptin, a cytokine-like peptide produced by adi-
pose tissue in proportion to adipose mass, acts on the
melanocortin system, inducing proopiomelanocortin
(POMC)6 synthesis in the hypothalamic arcuate nucleus
(4 ). The action of POMC-derived peptides, -, -, and
-melanocyte–stimulating hormone (MSH), and adreno-
corticotropic hormone (ACTH), is mediated by a family of
guanosine triphosphate–binding protein receptors, one of
which, melanocortin receptor 4 (MC4R), is produced at
high concentrations within the central nervous system
and plays an important role in the control of food intake
and energy balance (4 ). The first compelling evidence that
the POMC gene is involved in the control of human
appetite came from a report of 2 defects in ACTH synthe-
sis and in POMC gene translation in 2 children affected by
hyperphagia and uncontrolled obesity (5 ). Investigation
of other POMCmutations confirmed the link between this
1
Facolta` di Scienze Motorie, Universita` degli Studi Parthenope di Napoli,
Naples, Italy.
2 Dipartimento di Biochimica e Biotecnologie Mediche and 4 Dipartimento
di Medicina Clinica e Sperimentale-CISRO, Universita` di Napoli Federico II,
Naples, Italy.
3 CEINGE Biotecnologie Avanzate S.C. a r.l., Naples, Italy.
5 Dipartimento S.P.E.S., Universita` del Molise, Campobasso, Italy.
*Address correspondence to this author at: Dipartimento di Biochimica e
Biotecnologie Mediche, Universita` di Napoli Federico II, Via Pansini 5, 80131
Naples, Italy. Fax 39-081-7462404; e-mail sacchetti@dbbm.unina.it.
Received January 5, 2005; accepted May 4, 2005.
Previously published online at DOI: 10.1373/clinchem.2005.047886
6 Nonstandard abbreviations: POMC, proopiomelanocortin; MSH, mela-
nocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; MC4R,
melanocortin receptor 4; 3-UTR, 3 untranslated region; and BMI, body mass
index.
Clinical Chemistry 51:8
1358–1364 (2005) Molecular Diagnostics
and Genetics
1358
gene and obesity in humans and mice (4, 6–9). Increased
food intake, obesity, and hyperinsulinemia are features of
MC4R knock-out mice (10, 11 ), and various MC4R mis-
sense and nonsense mutations have been reported in
patients with severe early-onset obesity (12–15). These
findings prompted us to study the POMC and MC4R
genes in relation to serum leptin concentrations and to
anthropometric measurements in a large group of se-
verely obese adults from southern Italy. Our aims were to
identify mutations in susceptibility genes in relation to
obesity and to identify subgroups in whom major genes
exert greater phenotypic effects (16 ).
Materials and Methods
participants
The obese group included 196 unrelated severely obese
individuals [111 females (56.6%) and 85 males (43.4%);
17–70 years of age] recruited by the outpatient clinic of the
Department of Clinical and Experimental Medicine, Uni-
versity “Federico II”, Naples, Italy. Except for a 28-year-
old African woman who had lived in Italy for the past 20
years, all participants were Caucasian and had lived in
southern Italy for at least 3 generations. Inclusion criteria
were no diabetes, no coronary heart disease, and severe
obesity classified as body mass index (BMI; weight/
height2)40.0 kg/m2. For all participants we obtained the
following measurements: BMI, waist and hip circumfer-
ence (in cm), and fat and fat-free mass by impedentiom-
etry (17 ) (STA/BIA; Akern). The general characteristics of
the obese group are reported in Table 1. Of the obese
participants, 91.2% had a familial history of disease:
obesity, 26.3%; obesity plus hypertension plus diabetes,
2.1%; hypertension, 14%; diabetes, 5.3%; hyperlipidemia,
2.3%; and neoplasia, 1.2%. As controls, 100 (34 males and
66 females) normal-weight healthy individuals (BMI 25
kg/m2; age range, 26–76 years) were recruited from the
Laboratory Medicine Hospital and underwent genetic
testing for obesity. These controls were also tested to
calculate the reference values for serum leptin.
Written informed consent was obtained from all par-
ticipants. The research was approved by the Ethics Com-
mittee of the School of Medicine, University of Naples
“Federico II” and was in accordance with the principles of
the Helsinki II Declaration.
genomic dna amplification and sequencing
Genomic DNA from obese and nonobese individuals was
extracted from whole blood (Nucleon BACC-2; Amer-
sham Biosciences Europe). The coding sequences of both
POMC and MC4R were amplified with primers chosen
by the PRIMER 3 program (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi). The primers were
selected to generate fragments encompassing POMC ex-
ons 1 and 2 and to obtain overlapping fragments of exon
3 of POMC and of MC4R gene transcripts. POMC was
amplified (GeneAmp PCR System 9700; Applied Biosys-
tems) in a final volume of 25 L containing a PCR mixture
[10 M each primer, 1 PCR buffer, 200 M each de-
oxynucleotide triphosphate, and 0.5 U of Taq DNA poly-
merase (Perkin-Elmer Cetus)] and 100 ng of genomic
DNA. The MC4R PCRs were performed with a final
volume of 50 L containing 50 ng of genomic DNA; 1 U
of Taq DNA polymerase (Invitrogen Life Technologies);
200 M each deoxynucleotide triphosphate, 50 mM KCl,
10 mM Tris-HCl (pH 8.8), 2.5 mM MgCl2, 0.2 g/mL
bovine serum albumin, and 10 M of the correspond-
ing primers (see the Appendix in the Data Supplement
at that accompanies the online version of this article
at http://www.clinchem.org/content/vol51/issue8). The
PCR fragments were separated by electrophoresis on a
1.5% agarose gel and purified. Both strands were then
sequenced in both directions (BigDye Terminator v3.1
cycle sequencing method on an ABI-Prism 3100 Genetic
Analyzer; Applied Biosystems). The POMC and MC4R
Table 1. General and biochemical characteristics of
severely obese adults, living in southern Italy, who were
studied (n  196).a
Males Females
No. 85 111
Age, years 32.3 (10.5) 32.4 (12.5)
BMI, kg/m2 48.2 (8.3) 49.3 (8.1)
Waist-to-hip ratio 1 (0.06)b 0.96 (0.07)
Fat-free mass,c % 56.9 (5.4)b 48.3 (6.0)
Fat mass,c % 43.1 (5.5)b 51.7 (6.8)
Systolic blood pressure, mmHg 134.1 (16)b 123.2 (16)
Diastolic blood pressure, mmHg 85.9 (10)b 79.3 (10)
Heart rate, beats/min 79.8 (12) 78.8 (10)
Total cholesterol, mmol/L 4.5 (0.8)d 4.9 (1.0)
HDL-cholesterol, mmol/L 1.0 (0.2)b 1.2 (0.2)
LDL-cholesterol, mmol/L 2.8 (0.8) 3.0 (0.9)
Triglycerides, mmol/L 1.7 (1.1) 1.5 (0.6)
AST,e U/L 29.9 (13.0)d 24.6 (14.2)
ALT, U/L 52.6 (31.5)b 32.1 (22.3)
Leptin,f g/L 67.6 (48.1)b 141.5 (54.4)
Insulin, mIU/L 26.9 (18.5)d 20.3 (9.5)
Glucose, mmol/L 5.4 (1.8) 5.1 (0.8)
HOMAg 6.5 (4.4)b 4.6 (2.4)
TSH, mIU/L 1.7 (0.8) 2.3 (2.5)
FT3, ng/L 2.9 (0.5) 2.9 (0.5)
FT4, ng/L 62 (51) 59 (53)
ACTH, ng/L 39.9 (37.7) 24.4 (11.1)
Cortisol,h g/L 136.7 (44.8) 133.2 (59.8)
a All values are the mean (SD).
b P 0.001.
c Measured in 86 patients (39 males and 47 females).
d P 0.05.
e AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA,
homeostasis model assessment; TSH, thyroid-stimulating hormone; FT3, free
triiodothyronine; FT4, free thyroxine.
f Reference intervals for normal-weight controls (see the section on patients in
the Materials and Methods) were 1.1–19.7 g/L in males and 2.3–56.1 g/L in
females.
g HOMA: fasting insulin (mIU/L)/22.5  eln(glucose, in mmol/L).
h Measured in plasma, whereas all other biochemical values were measured
in fasting serum.
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nucleotide and amino acid sequences were numbered
according to nucleotide 1 in the reference sequence (Gen-
Bank accession nos. V01510 and NP_000930 for POMC;
S77415 and P32245 for MC4R). Mutations were named
according to standard guidelines (18 ). We confirmed the
MC4R mutations by restriction fragment length polymor-
phism mapping (Q43X, W174C, and S19fsX51) and with
the amplification refractory mutation system (I317V). For
further details, please contact the corresponding author.
hplc analysis
To analyze the 9- and 18-bp insertion (codons 93–99)
polymorphisms in exon 3 of the POMC gene, we designed
amplification primers using the PRIMER 3 program (for-
ward, 5-GTCTTCCCCCAGGAGTGC-3; reverse, 5-
AGACGTCCTCGCGCTTCT-3). The analysis was per-
formed according to standard procedures with the WAVE
DNA Fragment Analysis System (3500 HT; Trans-
genomic).
protein truncation test
We verified the presence of the E244X mutation in POMC
with the in vitro protein truncation test by adding 5 L of
PCR product and 1 L of [3H]leucine to a reticulocyte
lysate (Promega) under the manufacturer’s recommended
reaction conditions. The upstream primer contained eu-
karyotic signals for efficient transcription and translation
(the T7 promoter sequence and a translation initiation
site). The oligonucleotide sequences were 5-T7-GAGTG-
CATCCGGGCCTGCAAG-3 for the amplification of frag-
ment B and 5-CGATCCATGCTGCTGTTATTT-3 for the
3 untranslated region (3-UTR). The PCR was performed
as follows: 1 cycle at 94 °C (5 min); 35 cycles at 94 °C (30
s), 60 °C (30 s), 72 °C (45 s); and 10 min of final extension
at 72 °C. The molecular masses of the PCR products
(wild-type and mutant) were assessed by electrophoresis
on a 1.5% agarose gel. A 9-L aliquot of the reaction
products was denatured with 3 L of loading buffer and
loaded on a 15% sodium dodecyl sulfate–polyacrylamide
gel. The molecular masses of the mutated and wild-type
peptides were assigned based on comparison with molec-
ular mass calibrators (range, 6.9–205 kDa; Kaleidoscope
Prestained Standard; Bio-Rad Laboratories) analyzed un-
der the same experimental conditions. The gel was then
fixed, dried, and autoradiographed.
biochemical assays
Serum leptin concentrations were measured in duplicate
in obese and control individuals with a human leptin
enzyme immunoassay (Linco Research). Total cholesterol
and triglyceride concentrations were measured by stan-
dard enzymatic methods (19, 20 ). HDL was measured
after precipitation of LDL-cholesterol, and LDL-choles-
terol was calculated according to the Friedewald formula.
Thyroid-stimulating hormone, free triiodothyronine, and
free thyroxine concentrations were measured by immu-
noassay (Abbott Laboratories). Serum insulin, cortisol,
and ACTH were measured by chemiluminescence meth-
ods (Immulight 2000; Medical System). Glucose was mea-
sured by the hexokinase method. In each participant, the
degree of insulin resistance was estimated at baseline by
homeostasis model assessment as reported elsewhere
(21 ). Transaminase (aspartate transaminase and alanine
transaminase) activities were measured with the IFCC
enzymatic colorimetric method.
statistical analysis
Variables that were not gaussian distributed were loga-
rithmically transformed before statistical analyses (SPSS
for Windows, Ver. 11.5; SPSS). Continuous variables are
reported as the mean (SD), and categorical variables are
reported as percentages. Comparisons among variables
measured in females and males were performed with the
unpaired t-test or 2 test. Differences among groups were
considered statistically significant at P 0.05.
prediction study of protein structure
We performed a prediction study of the secondary struc-
ture of the mutated -MSH peptide and MC4R protein
with the GOR4 program (ABS-NIH) and used the PSI-
BLAST multiple sequence program (22 ) for alignment of
the protein sequences.
Results
Fasting serum hormone concentrations and biochemical
indices evaluated in the severely obese adults examined
in this study are reported in Table 1. Serum thyroid-
stimulating hormone, free triiodothyronine, free thyrox-
ine, ACTH, and cortisol values were within the reference
intervals for healthy individuals in all obese patients.
Serum leptin reference intervals obtained in our nonobese
participants were 1.1–19.7 g/L in males and 2.3–56.1
g/L in females. In obese males and females, serum
leptin concentrations were, respectively, 3.4 and 2.5 times
higher than the upper reference limits obtained in our
nonobese participants. The prevalence of the metabolic
syndrome (23 ) was 61% in males and 67% in females and
was diagnosed when at least 3 of the following 5 factors
were outside the reference values: waist circumference,
blood pressure, triglyceride and HDL-cholesterol concen-
trations, and glycemia.
As shown in Table 2, POMC or MC4R polymorphisms
were found in 53.5% of obese and in 53.0% of nonobese
participants. For POMC exon 3, we detected a 9-bp
insertion and an 18-bp insertion between codons 93 and
99, respectively: AGC AGC CGC (S-S-G) and AGC AGC
CGC AGC AGC CGC (S-S-G-S-S-G); the 8246CT poly-
morphism within the 3-UTR; and the silent polymor-
phism 4512CT (C6C) in exon 2. Obese females with the
8246CT or TT polymorphism had lower triglyceride
concentrations and higher HDL-cholesterol concentra-
tions than obese females with the 8246CC polymor-
phism (P 0.003; data not shown). We detected the
T112M and I103V polymorphisms in the MC4R gene
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product. The former variant was present in only 1 obese
patient, whereas the latter variant was present in 1 obese
individual and in 2 nonobese individuals. We found no
association between the metabolic syndrome and POMC/
MC4R polymorphisms.
POMC and MC4R mutations were present in 8 of the
196 obese individuals: 3 had POMC mutations (2 novel
and 1 known mutation), and 5 had MC4R mutations (4
novel and 1 known mutation). No mutations were found
in our normal-weight adults. The phenotypic characteris-
tics of mutation-carrying patients are reported in Table 3.
In case 1, we detected the heterozygous missense muta-
tion R236G, which disrupts a dibasic processing site
between -MSH and -endorphin and so produces a
mutant -MSH/-endorphin fusion protein (7, 8 ). The
individual was wild type for the MC4R gene. Case 2 had
the novel POMC heterozygous mutation P231L in -MSH.
The prediction study of the secondary structure of the
P231L peptide indicated an increase in the extended
strand structure (55.56% vs 38.89%) and a decrease in the
random coil structure (44.44% vs 61.11%) for the mutated
vs the wild-type peptide. Protein sequence alignment
Table 2. Mutations and polymorphisms detected in the POMC and MC4R genes in severely obese adults (n  196) and
nonobese controls (n  100) living in southern Italy.
Amino acid change Nucleotide change Obese, n (%) Lean, n (%)
POMC (exon 3)
Mutations P231La 8072CT 1 (0.5) 0
R236Gb 8086CG 1 (0.5) 0
E244Xa,c 8110GT 1 (0.5) 0
Polymorphisms 93–99 7658–7677 (ins AGC AGC CGC)d 20 (10.2) 6 (6)
93–99 7658–7677 ins (AGC AGC CGC)2 1 (0.5) 0
3-UTR 8246CT 65 (33.1) 33 (33)
3-UTR 8246TT 9 (4.6) 10 (10)
93–99/3-UTR 7658–7677 (ins AGC AGC CGC)/8246CT 7 (3.6) 2 (2)
C6C/3-UTR 4512eCT/8246CT 1 (0.5) 0
MC4R
Mutations W174Ca,f 915GC 1 (0.5) 0
Q43Xa 520CT 1 (0.5) 0
A175Tb,c 916GA 1 (0.5) 0
S19fsX51a 448delA 1 (0.5) 0
I317Va,b 1342AG 1 (0.5) 0
Polymorphisms T112M 728 CT 1 (0.5) 0
I103V 700 AG 1 (0.5) 2 (2)
a New mutation.
b 8246CT.
c POMC polymorphism 7658–7677 bp (ins 9 bp) also present in the mutated DNA.
d This variant (ins AGC AGC CGC) was detected in the homozygous state only in 1 of 196 obese persons.
e POMC exon 2 polymorphism.
f 8246TT.
Table 3. Phenotypic characteristics of mutation-carrying obese patients in southern Italy.
BMI,
kg/m2 Family history of disease






Case 1b 52.0 Obesity (f  m); diabetes (f) 21 4.2 82.2 R236G; 8246CT (3-UTR) WT
Case 2b 60.0 Obesity (f  m) 18 4.3 117.0 P231L WT
Case 3c 48.2 Not reported 20 6.8 101.2 E244X; 7658–7677
(ins AGC AGC CGC)d
WT
Case 4b 59.0 Overweight (f  m); hyperlipidemia
and diabetes (f)
8 3.9 36.1 8246TT (3-UTR) W174C
Case 5 45.7 Obesity (f  m) 10 1.3 99.1 WT Q43X
Case 6 47.7 Diabetes (m) 10 7.7 52.9 8246CT (3-UTR); 7658–7677
(ins AGC AGC CGC)d
A175T
Case 7 44.0 Obesity (f  m) 18 3.9 43.3 WT S19fsX51
Case 8 39.2 Hypertension (m) 10 1.9 47.9 8246CT (3-UTR) I317V
a HOMA, homeostasis model assessment; f, father; m, mother; WT, wild type.
b Correlated diseases: case 1, hypertension plus cholelithiasis, bilateral coxarthrosis, and spondyloarthrosis; case 2, hypertension; case 4, impaired fasting glucose.
c Obese African female living in Italy for the last 20 years.
d This variant (ins AGC AGC CGC) was detected in the homozygous state in case 3 and in the heterozygous state in case 6.
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indicated that, in addition to the H-F-R-W core sequence,
proline at residue 231 was also highly conserved (22 )
among different mammalian and nonmammalian species
(human, pig, sheep, cow, horse, rat, mouse, pigtailed
macaque, American mink, African elephant, frog, African
clawed frog, chicken, and ostrich). The individual was
wild type for the MC4R gene.
Case 3 carried a novel POMC heterozygous nonsense
mutation that introduces a stop codon in the -endorphin
peptide (E244X) and the above-described 9-bp insertion
(AGC AGC CGC, S-S-G) between codons 93 and 99 in
homozygosity. After retrotranscription and translation of
this mutated DNA, we verified by the protein truncation
test that this variant caused the synthesis of a truncated
peptide shorter (	22.0 kDa) than the wild-type peptide
(	24.4 kDa; Fig. 1). The participant was wild type for the
MC4R gene and was the only black non-Italian individual
attending our outpatient clinic.
Case 4 carried the MC4R heterozygous missense mu-
tation W174C. This mutation was not found in our non-
obese participants, nor has it been reported in other
Mediterranean obese and nonobese individuals (12, 13).
The prediction study of the secondary structure of the
W174C peptide indicated a slight decrease in the ex-
tended strand structure of the mutated fragment vs the
wild-type peptide. Case 5 was wild type for the POMC
gene and had a novel MC4R heterozygous nonsense
mutation that introduces a stop codon (Q43X) and pro-
duces a truncated N-terminal peptide. In case 6, we
identified the previously reported MC4R heterozygous
missense mutation A175T, which has been associated
with partial activity of the protein (24, 25).
Case 7 was wild type for the POMC gene and had a
1-bp deletion (448delA) in the MC4R gene that causes a
frameshift after codon 18 and introduces a premature stop
codon at codon 51 (S19fsX51). Only the first 18 of 51
amino acids of the truncated peptide belong to the wild-
type protein. For the MC4R gene, case 8 carried a novel
heterozygous missense mutation, I317V, located in the
C-terminal region of the protein. Protein sequence align-
ment indicated that the isoleucine residue was highly
conserved among different mammalian species (22 ).
Discussion
We identified POMC mutations in 3 of our severely obese
adults. Mutation R236G, in exon 3, is a known mutation
that comprises part of the conserved dibasic amino acid
cleavage site, K235-R236, which is recognized by prohor-
mone convertase 2. It is associated with altered POMC
processing and produces a -MSH/-endorphin fusion
protein, which is less able than the wild type to activate
the MC4R gene (8 ). R236G was reported to cosegregate
with early-onset obesity in 0.76% (2 of 262) of British
obese individuals (BMI standard deviation score 2.5). In
the latter study, the mutation was not present in 412
unrelated nonobese individuals; moreover, in 1 of the 2
patients with mutations, the variant cosegregated with
obesity in the family over a period of 3 generations (8 ). In
a French study, R236G was present in 1.65% (3 of 182) of
individuals (mean BMI 31.8 kg/m2) in association with
early-onset obesity and in 1.04% of controls (8 ). R236G
was also detected in 1.15% (1 of 87) of obese Italian
children (BMI standard deviation score 
 3.43) (9 ). Inter-
estingly, it was also identified in 0.6% (1 of 156) of
individuals in a Danish study of juvenile-onset obesity
(BMI 
 35.8 kg/m2) diagnosed when the individual was
	20 years of age (7 ), which coincides with our heterozy-
gous carrier of this variant, a female diagnosed as obese at
21 years of age.
The second novel mutation we identified in an obese
participant is a heterozygous variant in POMC exon 3 that
produces the P231L change in the -MSH peptide. Given
the predicted secondary structure of this mutated 18-
amino acid peptide, the proline3leucine exchange could
modify the secondary structure of the core melanocortin
sequence H-F-R-W (26 ). The -MSH peptide binds to
MC4R, via its core sequence, with a significantly higher
affinity than -MSH and is reported to be the key ligand
for MC4R that regulates feeding (27 ). Because both the
core sequence and proline residue 231 are highly con-
served among species, we suggest that the leucine substi-
tution alters the ligand affinity to MC4R and so contrib-
uted to obesity in our patient. A functional study is
required to verify this hypothesis.
The third novel mutation we identified is a heterozy-
gous nonsense mutation in POMC exon 3 that encodes a
truncated -endorphin peptide at codon 244. It is well
known that most nonsense transcripts are recognized and
efficiently degraded by nonsense-mediated mRNA decay
(28 ). This pathway may cause disease either by inducing
haploinsufficiency and/or a via dominant-negative effect
Fig. 1. Screening by protein truncation test of POMC exon 3 transcripts
from the patients with mutations (lane 1, case 3) and 2 nonobese
controls (lanes 2 and 3).
The variant introduced a stop codon at position E244 in the protein. In the
heterozygous patient (lane 1; case 3) we observed 2 different peptides: the
wild-type peptide (	24.4 kDa), which was also present in the 2 controls (lanes
2 and 3), and the truncated peptide (	22.0 kDa). A prestained molecular mass
calibration mixture (6.9–205 kDa) was used to estimate the molecular masses
of the peptides.
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of the mutated protein (28 ). Our patient may be affected
by a similar disease-associated mechanism. Interestingly,
-endorphin peptide knockout mice develop an increased
fat mass late in life (29 ), which coincides with the late-
onset obesity of our patient carrying the E244X mutation
in heterozygosity.
Mutations in MC4R cosegregate with severe early-
onset obesity and are the most common monogenic cause
of human obesity, with mutations spanning from caus-
ative, inactive, to partially active (12–15, 24, 25, 30–32).
We identified the A175T variant in the MC4R gene in a
severely obese young male (BMI 
 47.7 kg/m2) with
early-onset obesity (case 6). This variant was described in
a British individual with early-onset obesity; a family
history of obesity, insulin resistance, and euglycemia
associated with reduced MC4R activity (24 ); and a re-
duced ability to generate cAMP in response to ligand but
a normal or near-normal ligand binding affinity for
-MSH analogs (25 ).
The novel W174C mutation in MC4R, identified in a
severely obese male (case 4), lies in the fourth transmem-
brane segment of the protein, where it produces a change
of tryptophan (a highly conserved amino acid among
species) to cysteine. On the basis of the predicted second-
ary structure, W174C could alter the protein’s conforma-
tion.
Mutation S19fsX51 alters the N-terminal peptide of
MC4R. In fact, only the first 18 amino acids of the peptide
are conserved. Recent evidence indicates that, by acting as
an intramolecular ligand for the receptor, an intact NH2
terminus is required for receptor activity (33 ). Loss of
constitutive receptor has been associated with obesity in
humans (15, 32, 33 ).
The mutation Q43X encodes an MC4R protein trun-
cated from the first transmembrane domain onward.
Other stop-codon mutations have been described recently
(15, 32, 33 ); in particular, protein with the Y35X mutation
in the N-terminal region did not bind -MSH and showed
a relatively high allele frequency (0.6%) in a Danish obese
population (34 ). Presumably, our stop-codon mutation
could also be associated with no or partial MC4R activity.
The novel heterozygous missense mutation I317V is
located in the C-terminal region of MC4R. Despite the
structural similarity between isoleucine and valine, we
did not find I317V in nonobese participants. Highly
conserved among species, isoleucine-317 may exert an
important functional role. A functional study is required
to test whether this variant is associated with reduced
MC4R membrane expression and -MSH response as
shown for the I317T variant (14, 15, 31, 32, 35, 36 ).
In conclusion, we identified POMC mutations in 1.5% of
our severely obese adults, which coincides with the low
frequency of mutations reported previously for this gene
(	1% for the most frequent R236G variant) (8 ). These
mutations do not appear to be associated with early-onset
obesity in our population. We found MC4R mutations in
2.5% of our patients, a frequency similar to that reported
for other Caucasian populations affected by both early-
and adult-onset obesity, i.e., from 2% to 5.8% (4, 24, 25, 32,
34, 37 ), but higher than frequencies recently reported for
2 other Mediterranean obese populations, 0.5% and 1.7%
(12, 13 ).
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